These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 918547)

  • 1. Drug absorption and hepatic drug metabolism in patients with different types of intestinal shunt operation for obesity. A study with phenazone.
    Andreasen PB; Danö P; Kirk H; Greisen G
    Scand J Gastroenterol; 1977; 12(5):531-5. PubMed ID: 918547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of metronidazole on phenazone metabolism].
    Staiger C; Wang NS; de Vries J; Weber E
    Arzneimittelforschung; 1984; 34(1):89-91. PubMed ID: 6538427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenazone metabolism in patients with liver disease.
    Andreasen PB; Greisen G
    Eur J Clin Invest; 1976 Jan; 6(1):21-6. PubMed ID: 1253807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenazone metabolism during perfusion of isolated guinea pig liver.
    Tarnawski A; Goszcz A; Bogdał J; Barylak H; Mach T
    Pol J Pharmacol Pharm; 1978; 30(5):621-6. PubMed ID: 751005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of bed rest on the pharmacokinetics of phenazone.
    Elfström J; Lindgren S
    Eur J Clin Pharmacol; 1978 Jul; 13(5):379-83. PubMed ID: 668797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absorption and elimination of D-propoxyphene, acetyl salicylic acid, and phenazone in a combination tablet (Doleron): comparison between young and elderly subjects.
    Melander A; Bodin NO; Danielson K; Gustafsson B; Haglund G; Westerlund D
    Acta Med Scand; 1978; 203(1-2):121-4. PubMed ID: 626106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changes in drug elimination under the influence of perazine therapy (author's transl)].
    Petruch F; Schüppel R; Breyer U
    Arzneimittelforschung; 1976; 26(6):1154-5. PubMed ID: 9113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone.
    Orzechowska-Juzwenko K; Wiela A; Cieślińska A; Roszkowska E
    Cancer; 1987 May; 59(9):1607-10. PubMed ID: 3828961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of acute biliary pancreatitis on liver metabolism of phenazone].
    Hartleb M; Nowak A; Nowakowska-Duława E; Mańczyk I; Becker A; Kacperek T
    Pol Arch Med Wewn; 1990 Mar; 83(3):104-10. PubMed ID: 2216933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.
    Fabre D; Bressolle F; Goméni R; Bouvet O; Dubois A; Raffanel C; Gris JC; Galtier M
    Clin Pharmacokinet; 1993 Apr; 24(4):333-43. PubMed ID: 8491059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lactose malabsorption after bypass operation for obesity.
    Gudmand-Höyer E; Asp NG; Skovbjerg H; Andersen B
    Scand J Gastroenterol; 1978; 13(6):641-7. PubMed ID: 99806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenazone as a marker of liver-metabolic function in patients with acute leukemia.
    Wiela-Hojenska A; Orzechowska-Juzwenko K; Usnarska-Zubkiewicz L; Kotlarek-Haus S; Hurkacz M
    Int J Clin Pharmacol Ther; 1999 May; 37(5):234-7. PubMed ID: 10363621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.
    St Peter JV; Awni WM
    Clin Pharmacokinet; 1991 Jan; 20(1):50-65. PubMed ID: 2029802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism of phenazone in man after hydrocortisone administration.
    Elfström J; Lindgren S
    Eur J Clin Pharmacol; 1978 Mar; 13(1):69-72. PubMed ID: 639836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enflurane anesthesia and antipyrine metabolism.
    Duvaldestin P; Mauge F; Desmonts JM
    Clin Pharmacol Ther; 1981 Jan; 29(1):61-4. PubMed ID: 7460476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
    Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
    Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium malabsorption and absence of bone decalcination following intestinal shunt operation for obesity. A comparison of two types of operation.
    Danö P; Christiansen C
    Scand J Gastroenterol; 1978; 13(1):81-5. PubMed ID: 635450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of industrial lead poisoning on cytochrome P450 mediated phenazone (antipyrine) hydroxylation.
    Meredith PA; Campbell BC; Moore MR; Goldberg A
    Eur J Clin Pharmacol; 1977 Nov; 12(3):235-9. PubMed ID: 412677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetics of phenazone as an indicator of the metabolic capacity of the liver in patients with hyperthyroidism].
    Orzechowska-Juzwenko K; Bolanowski M; Gruszka S; Szymczak J
    Pol Tyg Lek; 1983 May 16-23; 38(20-21):643-5. PubMed ID: 6647129
    [No Abstract]   [Full Text] [Related]  

  • 20. The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women.
    Groen K; Horan MA; Roberts NA; Gulati RS; Miljkovic B; Jansen EJ; Paramsothy V; Breimer DD; van Bezooijen CF
    Clin Pharmacokinet; 1993 Aug; 25(2):136-44. PubMed ID: 8403737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.